NINA BHARADWAJ: Open Payments
NPI 1790541001 · FLAGSTAFF, AZ. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$2,128 in 98 payments from 20 companies in 2025. Trend: 2023 $0 · 2024 $203 · 2025 $2,128
Food & beverage: $2,128
| Company | Payments | Amount |
|---|---|---|
| AstraZeneca Pharmaceuticals LP | 15 | $329 |
| Regeneron Healthcare Solutions, Inc. | 15 | $293 |
| Takeda Pharmaceuticals U.S.A., Inc. | 9 | $248 |
| Genentech USA, Inc. | 8 | $218 |
| GENZYME CORPORATION | 7 | $214 |
| Novartis Pharmaceuticals Corporation | 10 | $165 |
| LEO Pharma Inc. | 6 | $147 |
| Azurity Pharmaceuticals, Inc. | 6 | $102 |
| Amgen Inc. | 5 | $84 |
| GlaxoSmithKline, LLC. | 3 | $62 |
Products named: DUPIXENT, Xolair, HYQVIA, TEZSPIRE, ADBRY, FASENRA, Rhapsido, ALVESCO.
Industry payments across AZ — which companies pay providers there.
